Pharmacological strategies for the prevention of car- diovascular events in these patients include ACE inhibitors, ARBs, thiazide and thiazide-like diuretics, -blockers (par- ticularly after MI), CCBs, antiplatelet drugs, and drugs for the treatment of dyslipidemia. The recent ACC Foundation/AHA guidelines recommend ACE inhibitors and/or -blockers, with the addition of drugs such as thiazide diuretics or CCBs for the management of high BP in patients with stable IHD.169 There are no special contraindications in hypertensive patients for the use of nitrates, antiplatelet or anticoagulant drugs, or lipid-lowering agents for the management of angina and the prevention of coronary events, except that in patients with uncontrolled severe hypertension who are taking anti- platelet or anticoagulant drugs, BP should be lowered without delay to reduce the risk of hemorrhagic stroke. 1. Patients with hypertension and chronic stable angina should be treated with a regimen that includes: (a) -blocker in patients with a history of prior MI (b) An ACE inhibitor or ARB if there is prior MI, LV systolicdysfunction,diabetesmellitus,orCKD;and (c) A thiazide or thiazide-like diuretic (Class I; Level of Evidence A). 2. The combination of a -blocker, an ACE inhibitor or ARB, and a thiazide or thiazide-like diuretic should also be considered in the absence of a prior MI, LV systolic dysfunction, diabetes mellitus, or proteinuric CKD (Class IIa; Level of Evidence B). 3. If -blockers are contraindicated or produce intolerable side effects, a nondihydropyridine CCB (such as diltia- zem or verapamil) may be substituted, but not if there is LV dysfunction (Class IIa; Level of Evidence B). 4. If either the angina or the hypertension remains un- controlled, a long-acting dihydropyridine CCB can be added to the basic regimen of -blocker, ACE inhibitor, and thiazide or thiazide-like diuretic. 